COPD Exacerbation Prevention — SCE Respiratory MCQ

Correct answer: A — Add inhaled corticosteroid to LAMA/LABA

The correct answer is A, add inhaled corticosteroid to LAMA/LABA. This patient has two moderate exacerbations in the past year despite optimised dual bronchodilator therapy, and a blood eosinophil count of 320 cells per microlitre, both of which are the discriminating features that identify a good candidate for stepping up to triple therapy. NICE guidance on COPD in over 16s recommends considering triple therapy (LAMA/LABA/ICS) when patients have day to day symptoms that adversely affect quality of life and have had two or more moderate exacerbations, or one severe exacerbation, in a year, and it specifically highlights that a higher blood eosinophil count makes a good response to ICS more likely. An eosinophil count above 300 cells per microlitre is the threshold most strongly associated with reduced exacerbation risk from adding ICS, reflecting an eosinophilic, steroid responsive inflammatory phenotype rather than the neutrophilic phenotype typical of most COPD. This combination of exacerbation frequency plus a raised eosinophil count is exactly the scenario in which ICS confers meaningful benefit without exposing a low eosinophil patient to unnecessary pneumonia risk. Why the other options are wrong: B, Continue dual bronchodilator without ICS: this ignores ongoing exacerbations and a favourable eosinophil profile that predicts ICS benefit, so it under-treats a patient at continued risk. C, Add chronic oral prednisone: long term oral corticosteroids are not recommended for COPD maintenance because of cumulative harms including osteoporosis, adrenal suppression, diabetes and infection, with no guideline support for chronic use. D, Start theophylline: theophylline is reserved for use after trials of inhaled therapy have failed or in patients unable to use inhaled treatment, given its narrow therapeutic index and interaction burden, not as the next step here. E, Add azithromycin despite no smoking cessation: prophylactic azithromycin requires smoking cessation, optimisation of standard inhaled therapy, and exclusion of contraindications such as QT prolongation before use, none of which have been met. Key point: two or more moderate exacerbations a year on LAMA/LABA plus a blood eosinophil count at or above 300 cells per microlitre identifies patients who should step up to inhaled triple therapy with ICS.

Reference: NICE Guideline NG115, Chronic obstructive pulmonary disease in over 16s: diagnosis and management, section on inhaled therapies and blood eosinophil count, updated 2019, https://www.nice.org.uk/guidance/ng115